| scholarly article | Q13442814 |
| P2093 | author name string | Jean-François Geschwind | |
| Julius Chapiro | |||
| Lynn Jeanette Savic | |||
| Gregor Duwe | |||
| P2860 | cites work | Effects of glucose analogues (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors | Q78816393 |
| Acute toxicity and cardio-respiratory effects of 2-deoxy-D-glucose: a promising radio sensitiser | Q79856337 | ||
| Enhancement of cytotoxic and pro-apoptotic effects of 2-aminophenoxazine-3-one on the rat hepatocellular carcinoma cell line dRLh-84, the human hepatocellular carcinoma cell line HepG2, and the rat normal hepatocellular cell | Q82468872 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| HIF-1: upstream and downstream of cancer metabolism | Q24647482 | ||
| Cancer cell metabolism: implications for therapeutic targets | Q27013632 | ||
| Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells | Q28237181 | ||
| A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors | Q28281237 | ||
| A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth | Q28283339 | ||
| Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells | Q28477764 | ||
| Dichloroacetate enhances adriamycin-induced hepatoma cell toxicity in vitro and in vivo by increasing reactive oxygen species levels | Q28537767 | ||
| Aerobic glycolysis: meeting the metabolic requirements of cell proliferation | Q29615178 | ||
| Hepatocellular carcinoma | Q29616359 | ||
| On respiratory impairment in cancer cells | Q29617276 | ||
| Optimization of tumour radiotherapy: Part V--Radiosensitization by 2-deoxy-D-glucose and DNA ligand Hoechst-33342 in a murine tumour | Q33179815 | ||
| The non-competitive inhibition of brain hexokinase by glucose-6-phosphate and related compounds. | Q33968922 | ||
| Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies | Q34081705 | ||
| Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIb: Therapy response monitoring in colorectal and lung tumours, head and neck cancer, hepatocellular carcinoma and sarcoma | Q34252340 | ||
| Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. | Q34355664 | ||
| Glucose catabolism in African trypanosomes. Evidence that the terminal step is catalyzed by a pyruvate transporter capable of facilitating uptake of toxic analogs. | Q34360049 | ||
| Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase | Q34517998 | ||
| Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. | Q34525433 | ||
| Assessment of Tumoricidal Efficacy and Response to Treatment with18F-FDG PET/CT After Intraarterial Infusion with the Antiglycolytic Agent 3-Bromopyruvate in the VX2 Model of Liver Tumor | Q35111997 | ||
| DCA promotes progression of neuroblastoma tumors in nude mice | Q35402620 | ||
| Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors | Q35684292 | ||
| Human hepatocellular carcinoma in a mouse model: assessment of tumor response to percutaneous ablation by using glyceraldehyde-3-phosphate dehydrogenase antagonists | Q35773581 | ||
| Enhanced radiosensitivity and chemosensitivity of breast cancer cells by 2-deoxy-d-glucose in combination therapy. | Q36091997 | ||
| Transcatheter Intraarterial Therapies: Rationale and Overview | Q36104314 | ||
| MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors | Q36489907 | ||
| Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma | Q36557906 | ||
| Protective effect on normal brain tissue during a combinational therapy of 2-deoxy-d-glucose and hypofractionated irradiation in malignant gliomas. | Q36886481 | ||
| The multifunctional protein glyceraldehyde-3-phosphate dehydrogenase is both regulated and controls colony-stimulating factor-1 messenger RNA stability in ovarian cancer | Q36982940 | ||
| Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is pyruvylated during 3-bromopyruvate mediated cancer cell death | Q37095961 | ||
| Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study | Q37384240 | ||
| Targeting the hypoxia-inducible factor (HIF) pathway in cancer. | Q37587446 | ||
| Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer | Q37627652 | ||
| Clinical studies for improving radiotherapy with 2-deoxy-D-glucose: present status and future prospects. | Q37653797 | ||
| Glyceraldehyde-3-Phosphate Dehydrogenase: A Promising Target for Molecular Therapy in Hepatocellular Carcinoma | Q38042261 | ||
| Anticancer efficacy of the metabolic blocker 3-bromopyruvate: specific molecular targeting | Q38069803 | ||
| Intraarterial therapies for primary liver cancer: state of the art. | Q38149993 | ||
| Tumor glycolysis as a target for cancer therapy: progress and prospects | Q38168262 | ||
| Treatment of intermediate-stage hepatocellular carcinoma | Q38236876 | ||
| Dichloroacetate and cancer: new home for an orphan drug? | Q38243367 | ||
| 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy | Q38248897 | ||
| Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration | Q38935553 | ||
| Glycolysis inhibitor 2-deoxy-D-glucose suppresses carcinogen-induced rat hepatocarcinogenesis by restricting cancer cell metabolism | Q38940589 | ||
| Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer | Q38946885 | ||
| A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors. | Q39030297 | ||
| Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer | Q39175658 | ||
| Antiglycolytic Therapy Combined with an Image-guided Minimally Invasive Delivery Strategy for the Treatment of Breast Cancer | Q39181279 | ||
| Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. | Q39284220 | ||
| How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? | Q39434937 | ||
| Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis | Q39596455 | ||
| 3-Bromopyruvate induces endoplasmic reticulum stress, overcomes autophagy and causes apoptosis in human HCC cell lines | Q39714638 | ||
| Modulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: implications for cancer therapy | Q39763426 | ||
| GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis | Q39872802 | ||
| Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells : ROS-mediated cell death by 3-BrPA. | Q39907305 | ||
| Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model | Q40016083 | ||
| Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells | Q40048868 | ||
| 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs | Q41129737 | ||
| Differential responses of tumors and normal brain to the combined treatment of 2-DG and radiation in glioablastoma | Q43222513 | ||
| Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions | Q44647527 | ||
| Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. | Q44885846 | ||
| Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. | Q45973092 | ||
| Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate | Q46302698 | ||
| Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization | Q46467546 | ||
| Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme | Q46619159 | ||
| Improving cancer radiotherapy with 2-deoxy-D-glucose: phase I/II clinical trials on human cerebral gliomas | Q49041589 | ||
| Value of 18F-FDG PET/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE. | Q51029491 | ||
| Intraarterial Therapy with a New Potent Inhibitor of Tumor Metabolism (3-bromopyruvate): Identification of Therapeutic Dose and Method of Injection in an Animal Model of Liver Cancer | Q60531739 | ||
| Dichloroacetate as treatment for congenital lactic acidosis | Q67409023 | ||
| Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose | Q78334213 | ||
| P433 | issue | 1 | |
| P921 | main subject | liver cancer | Q623031 |
| systemic therapy | Q1929812 | ||
| P304 | page(s) | 19-28 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Hepatic oncology | Q27725477 |
| P1476 | title | Targeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond? | |
| P478 | volume | 3 |
| Q47374569 | AKT-mediated phosphorylation of ATG4B impairs mitochondrial activity and enhances the Warburg effect in hepatocellular carcinoma cells |
| Q89068528 | Glycine N-methyltransferase deletion in mice diverts carbon flux from gluconeogenesis to pathways that utilize excess methionine cycle intermediates |
| Q51383074 | Hyper-O-GlcNAcylation of YB-1 affects Ser102 phosphorylation and promotes cell proliferation in hepatocellular carcinoma. |
| Q59808915 | Kaempferol inhibits proliferation, migration, and invasion of liver cancer HepG2 cells by down-regulation of microRNA-21 |
| Q36211604 | Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study |
Search more.